BFC Planning’s ClearPoint Neuro CLPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.7K Hold
2,512
– – ﹤0.01% 1805
2026
Q2
$44.8K Buy
2,512
+2,185
+668% +$27.3K ﹤0.01% 1611
2026
Q1
$2.98K Hold
327
– – ﹤0.01% 2496
2025
Q4
$4.47K Hold
327
– – ﹤0.01% 2389
2025
Q3
$7.12K Hold
327
– – ﹤0.01% 2073
2025
Q2
$3.9K Hold
327
– – ﹤0.01% 2140
2025
Q1
$3.89K Sell
327
-113
-26% -$1.76K ﹤0.01% 2104
2024
Q4
$6.77K Sell
440
-196
-31% -$2.54K ﹤0.01% 1917
2024
Q3
$7.13K Buy
+636
New +$6.09K ﹤0.01% 1876

Other funds holding CLPT

BFC Planning's CLPT Position: Q3 2026 in Review

BFC Planning held its ClearPoint Neuro (CLPT) position steady in Q3 2026 at 2,512 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1805.

BFC Planning first reported a position in CLPT in Q3 2024 and has held it in 9 quarters since. The position peaked at $44.8K in Q2 2026. 95 funds tracked by Wall St. Rank hold CLPT as of Q3 2026.

  • BFC Planning held 2,512 shares of ClearPoint Neuro worth $30.7K as of Q3 2026.
  • BFC Planning left its ClearPoint Neuro share count unchanged in Q3 2026.
  • ClearPoint Neuro made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1805 holding.
  • BFC Planning first reported a position in ClearPoint Neuro in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's ClearPoint Neuro position peaked at $44.8K in Q2 2026.
  • 95 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.